Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma
RSC Medicinal Chemistry · 2026
DOI: 10.1039/d6md00465b ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Medicinal Chemistry, 2026. Verfasst von Gaurav Rai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Gandhinagar Palaj Campus, Palaj Gandhinagar-382055 Gujarat India priyak@iitgn.ac.in. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Education, India.
Abstract (Originalsprache)
A phenothiazine-based TTK inhibitor, G17b, overcomes temozolomide resistance in glioblastoma by triggering ROS-driven apoptosis, offering a CNS-penetrant starting point for future drug optimization.
Autor:innen und Institutionen
- Department of Chemistry, Indian Institute of Technology Gandhinagar Palaj Campus, Palaj Gandhinagar-382055 Gujarat India priyak@iitgn.ac.in.
ORCID-Profile: Sivapriya Kirubakaran
Förderung
- Ministry of Education, India
Zitieren
APA
Rai, G., Khasa, D., & Kirubakaran, S. (2026). Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma. RSC Medicinal Chemistry. https://doi.org/10.1039/d6md00465b
Vancouver
Rai G, Khasa D, Kirubakaran S. Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma. RSC Medicinal Chemistry. 2026. doi:10.1039/d6md00465b
BibTeX
@article{Rai2026,
author = {Rai, Gaurav and Khasa, Deepika and Kirubakaran, Sivapriya},
title = {Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma},
journal = {RSC Medicinal Chemistry},
year = {2026},
doi = {10.1039/d6md00465b}
}
EUVIMED